Meiragtx Holdings
MeiraGTx Holdings PLC is a clinical-stage gene therapy biopharmaceutical company developing genetic medicines for neurodegenerative diseases, ocular disorders, and xerostomia. The company utilizes adeno-associated virus (AAV) viral vector technology and proprietary riboswitch gene regulation platforms to advance pipeline candidates for Parkinson's disease, amyotrophic lateral sclerosis (ALS), and inherited retinal diseases. Main revenue drivers comprise strategic biopharmaceutical collaboration payments, research development milestones, and licensing royalties from partners like Janssen and Sanofi. MeiraGTx targets neurologists, ophthalmologists, clinical trial research centers, and patients with rare genetic disorders across the United States and Europe. The company holds an innovative market position in viral vector manufacturing and synthetic riboswitch gene regulation technology. Headquartered in London, United Kingdom, MeiraGTx Holdings PLC is listed on the Nasdaq Stock Market.
2 of the funds FundTelligence covers report a position in Meiragtx Holdings.
- Legal name
- MEIRAGTX HOLDINGS PLC
- Sector
- Health Care
- Country
- United Kingdom
- Funds holding it
- 2
- Exposure themes
- Gene Therapy, Genetic Medicine, Precision Medicine & Genomics
Funds holding Meiragtx Holdings
- BlackRock iShares NASDAQ US Biotechnology UCITS ETF — BlackRock · 0.06 % (full portfolio disclosed, October 2026)
- KLP AksjeGlobal Small Cap Indeks — KLP · 0.01 % (partially disclosed portfolio, June 2026)